Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA advisers back Novo Nordisk genetic insulins, despite worries

This article was originally published in Scrip

Executive Summary

Novo Nordisk’s bid to get marketing approval from the US FDA for the company’s new long-lasting insulin got a lukewarm endorsement on 8 November from the agency’s panel of outside experts.

You may also be interested in...



FDA staff argue Avastin benefit in breast cancer not worth the risk

At the first day - 28 June - of the much-anticipated two-day hearing on whether the USFDA should no longer allow Avastin (bevacizumab) from Roche's US arm Genentech to be sold for use in combination with paclitaxel to treat metastatic HER2 negative breast cancer, officials from the agency's Center for Drug Evaluation and Research (CEDR) made much the same arguments they advanced last July in persuading a panel of outside experts to recommend that the indication be dropped (scripintelligence.com, 21 July 2010).

US FDA panel votes against Forest's nebivolol for heart failure

The US FDA's cardiovascular and renal drugs advisory committee on January 11th unanimously recommended to the agency that it not approve Forest Laboratories' application to market its beta blocker nebivolol as a treatment for chronic heart failure (CHF).

US House and Senate begin hammering out differences in health reform bills

Although the US Congress is technically in recess – the House of Representatives until January 12th and the Senate until January 19th – key lawmakers got down to work the week commencing January 4th, trying to hammer out the differences between the versions of health reform legislation passed by the two bodies. Only when the two vote in support of identical language can the measure move to President Barack Obama to be signed into law. The goal is to get that done by the end of this month, but it is not a firm deadline and the final votes may slip into February.

Topics

Related Companies

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel